Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: arena v. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
Raponi S, Ilari C, Della Starza I, Cappelli LV, Cafforio L, Piciocchi A, Arena V, Mariglia P, Mauro FR, Gentile M, Cutrona G, Moia R, Favini C, Morabito F, Rossi D, Gaidano G, Guarini A, Del Giudice I, Foà R. Raponi S, et al. Among authors: arena v. Br J Haematol. 2020 Jun;189(5):853-859. doi: 10.1111/bjh.16434. Epub 2020 Feb 16. Br J Haematol. 2020. PMID: 32064595 Free article.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Rigolin GM, Cavazzini F, Piciocchi A, Arena V, Visentin A, Reda G, Zamprogna G, Cibien F, Vitagliano O, Coscia M, Farina L, Gaidano G, Murru R, Varettoni M, Paolini R, Sportoletti P, Pietrasanta D, Molinari AL, Quaglia FM, Laurenti L, Marasca R, Marchetti M, Mauro FR, Crea E, Vignetti M, Gentile M, Montillo M, Foà R, Cuneo A; GIMEMA Group. Rigolin GM, et al. Among authors: arena v. Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26. Hematol Oncol. 2021. PMID: 33739461 Free PMC article. Clinical Trial.
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.
Puzzolo MC, Del Giudice I, Peragine N, Mariglia P, De Propris MS, Cappelli LV, Trentin L, Reda G, Cuneo A, Molica S, Piciocchi A, Arena V, Mauro FR, Guarini A, Foà R. Puzzolo MC, et al. Among authors: arena v. Front Oncol. 2021 Apr 15;11:637186. doi: 10.3389/fonc.2021.637186. eCollection 2021. Front Oncol. 2021. PMID: 33937038 Free PMC article.
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
Rigolin GM, Del Giudice I, Bardi A, Melandri A, García-Jacobo RE, Cura F, Raponi S, Ilari C, Cafforio L, Piciocchi A, Arena V, Reda G, Albano F, Molica S, Sportoletti P, Trentin L, Marchetti M, Nanni M, Peragine N, Mariglia P, Vignetti M, Guarini A, Mauro FR, Foà R, Cuneo A. Rigolin GM, et al. Among authors: arena v. Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883. Blood. 2021. PMID: 34587233 Free article. Clinical Trial. No abstract available.
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.
Cafforio L, Raponi S, Cappelli LV, Ilari C, Soscia R, De Propris MS, Mariglia P, Rigolin GM, Bardi A, Peragine N, Piciocchi A, Arena V, Mauro FR, Cuneo A, Guarini A, Foa R, Del Giudice I. Cafforio L, et al. Among authors: arena v. Haematologica. 2022 Jan 1;107(1):334-337. doi: 10.3324/haematol.2020.263715. Haematologica. 2022. PMID: 34647439 Free PMC article. No abstract available.
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol.
Buccisano F, Palmieri R, Piciocchi A, Arena V, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Capria S, Maurillo L, Del Principe MI, Paterno G, Irno Consalvo MA, Ottone T, Lavorgna S, Voso MT, Fazi P, Vignetti M, Arcese W, Venditti A. Buccisano F, et al. Among authors: arena v. Blood Adv. 2022 Apr 26;6(8):2510-2516. doi: 10.1182/bloodadvances.2021005717. Blood Adv. 2022. PMID: 34731884 Free PMC article. Clinical Trial.
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.
Fazio F, Cunsolo G, Mancini F, De Propris MS, Piciocchi A, Arena V, Messina M, Ansuinelli M, Taherinasab AT, Apicella V, Vitale A, Chiaretti S, Guarini A, Del Giudice I, Foà R. Fazio F, et al. Among authors: arena v. Leuk Lymphoma. 2022 Jun;63(6):1512-1514. doi: 10.1080/10428194.2022.2032035. Epub 2022 Feb 8. Leuk Lymphoma. 2022. PMID: 35133227 No abstract available.
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.
Innocenti I, Reda G, Visentin A, Coscia M, Motta M, Murru R, Moia R, Gentile M, Pennese E, Quaglia FM, Albano F, Cassin R, Deodato M, Ielo C, Frustaci AM, Piciocchi A, Rughini A, Arena V, Di Sevo D, Tomasso A, Autore F, Del Poeta G, Scarfò L, Mauro FR, Tedeschi A, Trentin L, Pompili M, Foà R, Ghia P, Cuneo A, Laurenti L. Innocenti I, et al. Among authors: arena v. Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325. Haematologica. 2022. PMID: 35199505 Free PMC article. No abstract available.
Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.
Buccisano F, Palmieri R, Piciocchi A, Arena V, Maurillo L, Del Principe MI, Paterno G, Irno-Consalvo MA, Ottone T, Divona M, Conti C, Fraboni D, Lavorgna S, Arcese W, Voso MT, Venditti A. Buccisano F, et al. Among authors: arena v. Haematologica. 2022 Dec 1;107(12):2823-2833. doi: 10.3324/haematol.2021.279777. Haematologica. 2022. PMID: 35295076 Free PMC article. Clinical Trial.
463 results